Been doing some digging into healthcare funds lately, and there's a pattern worth talking about. Most investors treat healthcare as their defensive play—and for good reason. Healthcare demand doesn't move much with the market cycle, which means your capital stays relatively protected even when things get messy elsewhere.

The thing about the healthcare sector is that a lot of these companies throw off steady dividends. When you see consistent payouts like that, it usually signals solid financials and reliable cash generation. That's exactly why healthcare funds appeal to people looking to build a diversified portfolio without having to pick individual stocks.

I've been tracking three funds that stand out. Fidelity Select Health Care (FSPHX) takes a global approach, focusing on companies in medical products and services. Their three-year returns sit around 6.8%, and they're holding 121 positions with Boston Scientific taking up about 6.5% of the portfolio. The fund managers use fundamental analysis to dig into financial strength and industry positioning.

Vanguard Health Care Fund (VGHCX) follows a similar playbook but with its own flavor. They're hitting 6.9% annualized returns over three years and keeping expenses low at 0.33%. This fund casts a wider net—they'll invest internationally and focus specifically on pharma manufacturers, medical equipment suppliers, and research organizations.

Now, if you want pure exposure to biotech upside, Fidelity Advisor Biotechnology Fund (FBTIX) is a different animal. The returns here are significantly higher at 18% annualized over three years, which makes sense given the sector volatility. Eirene Kontopoulos has been managing this fund since 2018, and it specifically targets companies driving scientific and tech advances in biotech.

What's interesting about healthcare funds right now is that they're offering both stability and growth potential depending on which angle you take. FSPHX and VGHCX give you that defensive healthcare play, while FBTIX lets you bet on biotech innovation. All three maintain non-diversified strategies focused purely on healthcare, which means you're getting concentrated exposure to this sector.

If you're considering healthcare funds for your portfolio, these three have solid track records. The healthcare space continues to benefit from demographic trends and ongoing innovation, so there's structural demand supporting these investments. Worth keeping on your radar if you're looking to add healthcare exposure.